Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 16 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
ERC1671 (Gliovac) for recurrent grade IV glioma	Bevacizumab (Avastin; R 435; RG 405; RG 435) , ERC1671 (Gliovac)	Glioma	Neurological Cancer	2019	View \| Download
Eflornithine with lomustine for treating recurrent anaplastic astrocytoma	Eflornithine (CPP-1X; Difluoromethylornithine; DFMO; Vaniqa; eflornithine hydrochloride monohydrate) , lomustine	Anaplastic astrocytoma	Neurological Cancer	2023	View \| Download
Depatuxizumab mafodotin for newly diagnosed EGFR‐amplified glioblastoma – first line	Depatuxizumab mafodotin (ABT-414) , Temozolomide (Temodar; Temodal; SCH 52365)	Glioma	Neurological Cancer	2018	View \| Download
Dabrafenib with trametinib for treating paediatric BRAF V600 mutated high-grade or low-grade glioma	Dabrafenib (Tafinlar; GSK2118436; dabrafenib mesilate) , Trametinib (Mekinist; TMT212; GSK-1120212B; GSK1120212; JTP-74057; trametinib dimethyl sulfoxide)	Glioma	Neurological Cancer	2022	View \| Download
Asinercept (Apocept) for glioblastoma multiforme for first or second line	Asunercept (Apocept; APG101)	Glioma	Neurological Cancer	2017	View \| Download
131I-omburtamab for neuroblastoma with central nervous system or leptomeningeal metastasis in paediatric patients	Omburtamab I-131 (131I-mu8H9)	Neuroblastoma	Neurological Cancer	2019	View \| Download